It can take several weeks to bounce back after a bout of COVID-19, but some people develop more persistent problems. The ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Key Takeaways The S&P 500 fell 0.4% on Tuesday, Dec. 31, 2024, stumbling into the finish line at the end of an upbeat year ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Of the 503 stocks in the S&P 500 (some companies have two classes of stocks that are included) fewer than 30% of them, or 148 ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Moderna ( MRNA) was the best-performing stock in the S&P 500 as Barron's called it "too cheap" and named the biotech firm as ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

According to Benzinga Pro, Moderna's peer group average for short interest as a percentage of float is 4.49%, which means the ...

Shares of Moderna Inc. MRNA shed 1.87% to $39.38 Monday, on what proved to be an all-around grim trading session for the ...